Navigation Links
Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
Date:9/12/2012

MOUNTAIN VIEW, Calif., Sept. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced positive results of a recently completed phase 2A study entitled, "Prospective Open Label Study of EPI-743 in Children with Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)." The study was conducted at the Ospedale Pediatrico Bambino Gesu– the Vatican's children's hospital, Rome, Italy.

Ten children with seven differing subtypes of Leigh syndrome, ranging in age from 1-13 years, were treated with EPI-743. All ten children exhibited reversal of disease progression as measured by four different disease-relevant metrics. The clinical response was durable over 180 days. No significant safety events were observed.

The results of the clinical trial were published on-line September 10, 2012 in the journal Molecular Genetics and Metabolism.

Findings obtained in this prospective phase 2 controlled study confirm previous clinical results obtained in the United States and Europe.

Leigh syndrome is an inherited lethal, progressive, predominately pediatric, neuromuscular disorder for which there are no approved treatments. Initially described in 1951, the hallmarks of the disease include bilateral necrosis (death) of central nervous system regions responsible for the control of breathing and other neurologic functions. Leigh syndrome belongs to a large family of disorders identified as "mitochondrial disease." The disorders share as a common biochemical feature defects in cellular energy metabolism.

EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of Leigh syndrome and other inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress.

Results obtained in this trial represent the first published report of disease reversal in an otherwise progressive and fatal neurological disease.

Edison Pharmaceuticals

Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases.


'/>"/>
SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... On ... its second COVID-19 drive-through testing shelter in Camden County, New Jersey. The new ... and Connor Strong & Buckelew and is located at 3100 Federal Street, across ...
(Date:5/21/2020)... FRANKFURT, Germany (PRWEB) , ... May 21, 2020 ... ... its enterprise blockchain expertise, announced the launch of the Corona SeroStatus app. Many ... with more than 4.7 million confirmed cases of coronavirus globally—including nearly 1.5 million ...
(Date:5/21/2020)... ... 2020 , ... Labyrinthe Labs has announced the launch of its brand new ... cream designed for fast-action relief of joint and muscle soreness, Lefa is botanically powered ... tired joints and muscles. , According to the National Institutes of Health ...
Breaking Medicine Technology:
(Date:5/27/2020)... FOWLERVILLE, Mich. (PRWEB) , ... May 27, 2020 , ... ... the Covid-19 curve and Howell Michigan, Fowlerville Michigan , and Ann Arbor Michigan. ... by seeing all high-risk patients within the clinic and at the hospital. We have ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... University of Washington Professor of Bioengineering, Founder & Editor of scientific journal ... Vapor ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water , * , ...
(Date:5/26/2020)... ... May 26, 2020 , ... ... of two leading RevSpring solutions—Talksoft® patient messaging and IVR Advantage™--for Loyale customers. ... patients through automated and precise texts, IVR reminders and email messages tailored ...
(Date:5/26/2020)... LOS ANGELES (PRWEB) , ... May 26, 2020 , ... ... speaker, and ageless sexuality advocate Joan Price have just received the 2020 AASECT Audio ... explicit sex education film was the first of its kind to feature non-actors in ...
(Date:5/25/2020)... ... May 23, 2020 , ... Winemaker Grant Long Jr. is introducing three Toilet ... whimsical and delicious in these complicated times,” he said, in announcing the new wines. ... ($24.99). The Chardonnay and Red Wine Blend are sourced in the Napa Valley; the ...
Breaking Medicine News(10 mins):